Helus Pharma Inc
R7E
Company Profile
Business description
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
Contact
100 King Street West
Suite 5600
TorontoONM5X 1C9
CANT: +1 866 292-4601
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2027
Employees
50
Stocks News & Analysis
stocks
Why great earnings haven't been good enough for AI hardware stocks
Stocks that had been posting triple-digit returns are sliding on earnings results.
stocks
Fair Value increased for Big 4 bank after earnings
Shares still overvalued, with analysts thinking the fundamentals no longer matter to the share price.
stocks
Chart of the Week: Why ASX tech is poised for a comeback
The “SaaSpocalypse” never arrived. Now, software stocks are positioning for a long-awaited comeback.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,348.40 | 42.10 | -0.45% |
| CAC 40 | 8,674.94 | 40.00 | -0.46% |
| DAX 40 | 26,331.07 | 60.35 | -0.23% |
| Dow JONES (US) | 53,770.27 | 21.58 | -0.04% |
| FTSE 100 | 10,833.15 | 11.04 | -0.10% |
| HKSE | 25,347.19 | 92.98 | -0.37% |
| NASDAQ | 26,588.49 | 143.04 | 0.54% |
| Nikkei 225 | 68,377.88 | 853.82 | 1.26% |
| NZX 50 Index | 13,812.83 | 75.17 | 0.55% |
| S&P 500 | 7,748.50 | 20.30 | 0.26% |
| S&P/ASX 200 | 9,151.50 | 41.40 | -0.45% |
| SSE Composite Index | 3,958.68 | 12.01 | 0.30% |